Research programme: CXCR4 inhibitors - Biokine

Drug Profile

Research programme: CXCR4 inhibitors - Biokine

Alternative Names: BKT-170

Latest Information Update: 29 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biokine Therapeutics
  • Class
  • Mechanism of Action CXCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hypertrophic scars; Inflammation
  • Discontinued Cancer

Most Recent Events

  • 28 Jan 2016 Discontinued - Preclinical for Cancer in Israel (Parenteral)
  • 28 Jan 2016 Preclinical trials in Hypertrophic scars in Israel (Topical, Paste and Gel)
  • 28 Jan 2016 Preclinical trials in Inflammation in Israel (Topical, Paste and Gel)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top